Drug Profile
Citrate/heparin/taurolidine - CorMedix Pharmaceuticals
Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Defencath; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrateLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator ND Partners
- Developer CorMedix
- Class Alkanesulfonic acids; Antibacterials; Anticoagulants; Antifungals; Citrates; Heparins; Small molecules; Thiadiazines
- Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Factor Xa inhibitors; Heparanase inhibitors; Inflammation mediator inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Catheter infections
Most Recent Events
- 12 Mar 2024 CorMedix plans a post-approval meeting to discuss clinical pathway of DefenCath® for an expanded label with the US FDA in mid-year 2024
- 08 Jan 2024 CorMedix plans to launch DefenCath for Catheter infections (Prevention) in USA by April 15, 2024 for the inpatient setting, and no sooner than July 1, 2024 for the outpatient setting
- 15 Nov 2023 Registered for Catheter infections (Prevention) in USA (unspecified route)